Skip to main content

TRUPANION, INC.

For the period ended Mar 31, 2026. Filed Apr 30, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed Apr 30, 2026

TRUP$35.50-3.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 1. Financial Statements

TRUPANION, INC.Condensed Consolidated Statements of Operations(in thousands, except share data)(unaudited)
Three Months Ended March 31,
20262025
Revenue$384,049$341,975
Cost of revenue:
Veterinary invoice expense(1)281,436247,450
Other cost of revenue(1)41,12443,422
Total cost of revenue322,560290,872
Operating expenses:
Technology and development(1)11,2948,072
General and administrative(1)19,10219,892
New pet acquisition expense(1)22,61120,516
Depreciation and amortization3,7063,791
Total operating expenses56,71352,271
Loss from investment in joint venture—(305)
Operating income (loss)4,776(1,473)
Interest expense1,8753,211
Other (income), net(3,055)(3,240)
Income (loss) before income taxes5,956(1,444)
Income tax expense1,07639
Net income (loss)$4,880$(1,483)
Net income (loss) per share:
Basic$0.11$(0.03)
Diluted$0.11$(0.03)
Weighted average shares of common stock outstanding:
Basic43,505,60442,775,955
Diluted43,681,74042,775,955
(1)Includes stock-based compensation expense as follows:
Veterinary invoice expense$560$770
Other cost of revenue569489
Technology and development1,5071,151
General and administrative4,8934,528
New pet acquisition expense1,4712,892
TRUPANION, INC.Condensed Consolidated Statements of Comprehensive Income(in thousands)(unaudited)
Three Months Ended March 31,
20262025
Net income (loss)$4,880$(1,483)
Other comprehensive income (loss):
Foreign currency translation adjustments(1,277)1,352
Net unrealized gain (loss) on available-for-sale investments(1,513)545
Other comprehensive income (loss), net of taxes(2,790)1,897
Comprehensive income$2,090$414
TRUPANION, INC.Condensed Consolidated Balance Sheets(in thousands, except share data)
March 31, 2026December 31, 2025
Assets · (unaudited)
Current assets:
Cash and cash equivalents$153,456$138,024
Short-term investments230,205232,706
Accounts and other receivables, net of allowance for credit losses of $2,419 at March 31, 2026 and $1,311 at December 31, 2025304,796301,945
Prepaid expenses and other assets16,70918,387
Total current assets705,166691,062
Restricted cash29,41633,434
Long-term investments986983
Property, equipment, and internal-use software, net102,612104,844
Intangible assets, net23,68424,102
Other long-term assets21,09521,237
Goodwill38,62139,382
Total assets$921,580$915,044
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$12,828$16,445
Accrued liabilities and other current liabilities42,32956,509
Reserve for veterinary invoices56,70155,921
Deferred revenue286,508270,935
Long-term debt - current portion10,00010,000
Total current liabilities408,366409,810
Long-term debt99,346101,784
Deferred tax liabilities9551,510
Other liabilities18,09118,004
Total liabilities526,758531,108
Stockholders’ equity:
Common stock: $0.00001 par value per share, 100,000,000 shares authorized; 44,648,800 and 43,620,614 issued and outstanding at March 31, 2026; 44,430,267 and 43,402,081 shares issued and outstanding at December 31, 2025——
Preferred stock: $0.00001 par value per share, 10,000,000 shares authorized; no shares issued and outstanding——
Additional paid-in capital613,624604,828
Accumulated other comprehensive income (loss)(693)2,097
Accumulated deficit(201,575)(206,455)
Treasury stock, at cost: 1,028,186 shares at March 31, 2026 and December 31, 2025(16,534)(16,534)
Total stockholders’ equity394,822383,936
Total liabilities and stockholders’ equity$921,580$915,044
Trupanion, Inc. Condensed Consolidated Statements of Stockholders' Equity(in thousands, except share amounts) (unaudited)
Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Treasury Stock · Total Stockholders' Equity
Shares · Amount
Balance at January 1, 202643,402,081$—$604,828$2,097$(206,455)$(16,534)$383,936
Issuance of common stock in connection with the Company's equity award programs, net of tax withholdings218,533—(236)———(236)
Stock-based compensation expense——9,032———9,032
Other comprehensive loss———(2,790)——(2,790)
Net income————4,880—4,880
Balance at March 31, 202643,620,614$—$613,624$(693)$(201,575)$(16,534)$394,822
Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Treasury Stock · Total Stockholders' Equity
Shares · Amount
Balance at January 1, 202542,488,445$—$568,302$(2,612)$(225,888)$(16,534)$323,268
Issuance of common stock in connection with the Company's equity award programs, net of tax withholdings287,510—112———112
Stock-based compensation expense——9,879———9,879
Other comprehensive income———1,897——1,897
Net loss————(1,483)—(1,483)
Balance at March 31, 202542,775,955$—$578,293$(715)$(227,371)$(16,534)$333,673

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

Three Months Ended March 31,
20262025
Operating activities
Net income (loss)$4,880$(1,483)
Adjustments to reconcile net income (loss) to cash provided by operating activities:
Depreciation and amortization3,7063,791
Stock-based compensation expense9,0009,830
Other, net(213)349
Changes in operating assets and liabilities:
Accounts and other receivables(3,035)(15,965)
Prepaid expenses and other assets1,954(204)
Accounts payable, accrued liabilities, and other liabilities(18,326)1,527
Reserve for veterinary invoices8422,407
Deferred revenue15,78615,712
Net cash provided by operating activities14,59415,964
Investing activities
Purchases of investment securities(47,883)(40,875)
Maturities and sales of investment securities48,87833,242
Purchases of property, equipment, and internal-use software(847)(1,928)
Other(35)588
Net cash provided by (used in) investing activities113(8,973)
Financing activities
Repayment of debt financing(2,500)(338)
Proceeds from exercise of stock options2601,024
Shares withheld to satisfy tax withholding(496)(915)
Other—(230)
Net cash used in financing activities(2,736)(459)
Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash, net(557)(52)
Net change in cash, cash equivalents, and restricted cash11,4146,480
Cash, cash equivalents, and restricted cash at beginning of period171,458199,530
Cash, cash equivalents, and restricted cash at end of period$182,872$206,010
Supplemental disclosures
Noncash investing and financing activities:
Purchases of property, equipment, and internal-use software included in accounts payable and accrued liabilities$340$803

Notes to the Condensed Consolidated Financial Statements (unaudited)

  1. Nature of Operations and Significant Accounting Policies

Description of Business and Basis of Presentation

Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the "Company") provides medical insurance for cats and dogs in the United States, Canada, and certain countries in Continental Europe. Through its data-driven, vertically-integrated approach, the Company develops and offers high-value medical insurance products, priced to take into account each pet's unique characteristics and coverage level.

The financial data as of December 31, 2025 was derived from the Company's audited consolidated financial statements. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") and, in management's opinion, have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company's financial position, results of operations, comprehensive income, stockholders' equity and cash flows for the interim periods. These unaudited interim consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission ("SEC") on February 13, 2026 (the "2025 10-K"). The Company's accounting policies are described in Note 1 to the audited financial statements included in the 2025 10-K. Operating results for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the full fiscal year or any other interim period.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. See Note 1 to the audited financial statements included in the 2025 10-K for additional discussion of these estimates and assumptions.

Recent Accounting Pronouncements

In November 2024, the FASB issued ASU 2024-03, which requires public business entities to disclose additional information about specific expense categories in the notes to the financial statements at interim and annual reporting periods. The ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is evaluating the impact of this ASU on its consolidated financial statements.

In September 2025, the FASB issued ASU 2025-06, which modernizes the accounting for software costs that are accounted for under Subtopic 350-40, Intangibles-Goodwill and Other-Internal-Use Software. The ASU is effective for annual periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. The Company is currently evaluating the impact of adopting ASU 2025-06.

  1. Net Income (Loss) per Share

Basic net income (loss) per share is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is calculated using the weighted average number of shares of common stock plus, when dilutive, potential shares of common stock outstanding using the treasury-stock method. Potential shares of common stock outstanding include stock options, and unvested restricted stock units.

The components of basic and diluted earnings per share were as follows (in thousands, except share and per share information):

Three Months Ended March 31,
20262025
Basic earnings per share:
Net income (loss)$4,880$(1,483)
Shares used in computation:
Weighted average shares of common stock outstanding43,505,60442,775,955
Basic earnings per share$0.11$(0.03)
Diluted earnings per share:
Net income (loss)$4,880$(1,483)
Shares used in computation:
Weighted average shares of common stock outstanding43,505,60442,775,955
Stock options77,240—
Restricted stock units98,896—
Weighted average number of shares43,681,74042,775,955
Diluted earnings per share$0.11$(0.03)

The following potentially dilutive equity securities were not included in the diluted earnings per share of common stock calculation because they would have had an antidilutive effect:

Three Months Ended March 31,
20262025
Stock options—267,452
Restricted stock units682,6231,472,290
  1. Investments

Available-for sale securities are classified as short-term versus long-term investments based on whether they represent the investment of funds available for current operations. Currently, all available-for-sale securities are considered short-term in nature. Held-to-maturity securities are classified as short-term versus long-term investments based on their maturity dates. The amortized cost, gross unrealized holding gains and losses, and estimated fair value of long-term and short-term investments by major security type and class of security were as follows as of March 31, 2026 and December 31, 2025 (in thousands):

AmortizedCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesFairValue
Long-term investments:
Held-to-maturity investments
U.S. treasury securities$986$—$—$986
$986$—$—$986
Short-term investments:
Available-for-sale investments
U.S. treasury securities$98,342$77$(367)$98,052
Mortgage-backed securities and collateralized mortgage obligations25,27998(46)25,331
Other asset-backed securities26,22188(27)26,282
Corporate bonds52,055191(150)52,096
$201,897$454$(590)$201,761
Held-to-maturity investments
U.S. treasury securities$9,779$1$(4)$9,776
Foreign treasury securities18,140—(16)18,124
Certificates of deposit525——525
$28,444$1$(20)$28,425
AmortizedCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesFairValue
Long-term investments:
Held-to-maturity investments
U.S. treasury securities$983$5$—$988
$983$5$—$988
Short-term investments:
Available-for-sale investments
U.S. treasury securities$103,643$523$(8)$104,158
Mortgage-backed securities and collateralized mortgage obligations24,501201(15)24,687
Other asset-backed securities23,685152—23,837
Corporate bonds47,311527(3)47,835
$199,140$1,403$(26)$200,517
Held-to-maturity investments
U.S. treasury securities$9,757$10$—$9,767
Foreign treasury securities18,263——18,263
Certificates of deposit4,169——4,169
$32,189$10$—$32,199

Future maturities of investments classified as available-for-sale and held-to-maturity are as follows (in thousands):

As of March 31, 2026
AmortizedCostFairValue
Available-for-sale:
Due under one year$5$5
Due after one year through five years150,392150,143
Due after five years through ten years——
Due after ten years——
$150,397$150,148
Available-for-sale collateralized:
Due under one year$9,785$9,823
Due after one year through five years31,49531,584
Due after five years through ten years10,0039,981
Due after ten years217225
$51,500$51,613
Held-to-maturity:
Due under one year$28,444$28,425
Due after one year through five years986986
$29,430$29,411

The following tables present the gross unrealized losses and related fair values for the Company's investment in available-for-sale securities, grouped by duration of time in a continuous unrealized loss position as of March 31, 2026 and December 31, 2025 (in thousands):

Less than 12 Months12 Months or MoreTotal
Fair ValueGross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
U.S. treasury securities$72,873$(367)$—$—$72,873$(367)
Mortgage-backed securities and collateralized mortgage obligations10,432(29)877(17)11,309(46)
Other asset-backed securities6,778(27)——6,778(27)
Corporate bonds22,150(150)——22,150(150)
Total$112,233$(573)$877$(17)$113,110$(590)
Less than 12 Months12 Months or MoreTotal
Fair ValueGross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
U.S. treasury securities$5,139$(8)$—$—$5,139$(8)
Mortgage-backed securities and collateralized mortgage obligations2,893(3)967(12)3,860(15)
Other asset-backed securities——————
Corporate bonds2,700(3)——2,700(3)
Total$10,732$(14)$967$(12)$11,699$(26)

As of March 31, 2026,70 of the securities held were in an unrealized loss position. Unrealized losses on available-for-sale investments relate to interest rate changes. The Company does not expect material credit losses from its available-for-sale investments, considering the composition of the investment portfolio and the credit rating of these investments. The Company determined it is not likely to, and does not intend to, sell securities currently in a loss position prior to a potential recovery of their cost basis. The Company does not expect material credit losses from its held-to-maturity investments, considering the composition of the investment portfolio and the credit loss history of these investments.

Proceeds from the sales of fixed maturity investments classified as available-for-sale were $39.3 million and $29.6 million during the three months ended March 31, 2026 and 2025, respectively.

  1. Fair Value

Fair Value Disclosures

The following table summarizes, by major security type, the Company's assets that are measured at fair value on a recurring basis, and placement within the fair value hierarchy (in thousands):

As of March 31, 2026
Fair ValueLevel 1Level 2Level 3
Assets
Money market funds$51,524$51,524$—$—
Fixed maturities:
Mortgage-backed securities and collateralized mortgage obligations25,331—25,331—
Other asset-backed securities26,282—26,282—
Corporate bonds52,096—52,096—
U.S. treasury securities98,052—98,052—
Total$253,285$51,524$201,761$—
As of December 31, 2025
Fair ValueLevel 1Level 2Level 3
Assets
Money market funds$46,818$46,818$—$—
Fixed maturities:
Mortgage-backed securities and collateralized mortgage obligations24,687—24,687—
Other asset-backed securities23,837—23,837—
Corporate bonds47,835—47,835—
U.S. treasury securities104,158—104,158—
Total$247,335$46,818$200,517$—

The Company measures the fair value of money market funds, classified as Level 1, based on quoted prices in active markets for identical assets. The fair values of the Company's fixed maturity investments classified as Level 2 are based on either recent trades in inactive markets or quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. Held-to-maturity investments are carried at amortized cost and the fair value and changes in unrealized gains and losses are disclosed in Note 3, Investments. The fair value of these investments is determined in the same manner as available-for-sale securities and are considered either a Level 1 or Level 2 measurement.

The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers between levels for the three months ended March 31, 2026 and the year ended December 31, 2025.

Fair Value Disclosures - Other Assets and Liabilities

The Company's other long-term assets balance also included notes receivable of $2.4 million and $2.5 million as of March 31, 2026 and December 31, 2025, respectively, recorded at their estimated collectible amount. The Company estimates that the carrying value of the notes receivable approximates the fair value. The estimated fair value represents a Level 3 measurement within the fair value hierarchy, and is based on market interest rates and the assessed creditworthiness of the third party.

The Company estimates the fair value of long-term debt based upon rates currently available to the Company for debt with similar terms and remaining maturities. This is a Level 3 measurement. Based upon the terms of the debt, the carrying amount of long-term debt approximated fair value at March 31, 2026.

  1. Commitments and Contingencies

Legal Proceedings

From time to time the Company is or may become subject to various legal proceedings arising in the ordinary course of business, including proceedings involving members, other entities or regulatory bodies. Estimated liabilities are recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. At this time, the Company does not believe any such matters to be material individually or in the aggregate. These views are subject to change following the outcome of future events or the results of future developments.

  1. Reserve for Veterinary Invoices

The reserve for veterinary invoices is an estimate of the future amount the Company will pay for insurance claims that have not been paid prior to the reporting date. The reserve also includes the Company's estimate of related internal processing costs. The reserve estimate involves actuarial projections and is based on management's assessment of facts and circumstances currently known, and assumptions about anticipated claims development patterns. The Company uses generally accepted actuarial methodologies, such as paid loss development methods, in estimating the amount of the reserve for veterinary invoices. The reserve is made for each of the Company's segments, subscription and other business, and is continually refined as the Company receives and pays veterinary invoices. Changes in management's assumptions and estimates may have a relatively large impact on the reserve and associated expense.

Reserve for veterinary invoices

Summarized below are the changes in total liability for the Company's subscription business segment (in thousands):

Three Months Ended March 31,
Subscription20262025
Reserve at beginning of year$26,364$23,084
Veterinary invoices during the period related to:
Current year188,274166,452
Prior years3,1401,729
Total veterinary invoice expense191,414168,181
Amounts paid during the period related to:
Current year168,898146,976
Prior years19,86517,870
Total paid188,763164,846
Non-cash expenses577832
Reserve at end of period$28,438$25,587

The Company had unfavorable development on veterinary invoice reserves of $3.1 million for the three months ended March 31, 2026, including unfavorable development of $0.1 million attributable to accident year 2025 and unfavorable development of $3.0 million attributable to accident year 2024 and prior. The unfavorable development for accident year 2024 and prior was primarily driven by higher than expected frequency of claims. Non-cash expenses are primarily comprised of stock-based compensation for employees performing claims processing related duties.

Summarized below are the changes in total liability for the Company's other business segment (in thousands):

Three Months Ended March 31,
Other Business20262025
Reserve at beginning of year$29,557$28,551
Veterinary invoices during the period related to:
Current year86,27683,822
Prior years3,746(4,553)
Total veterinary invoice expense90,02279,269
Amounts paid during the period related to:
Current year64,69261,307
Prior years26,62418,058
Total paid91,31679,365
Non-cash expenses——
Reserve at end of period$28,263$28,455

The Company had unfavorable development on veterinary invoice reserves for the other business segment of $3.7 million for the three months ended March 31, 2026, including unfavorable development on veterinary invoice reserves of $2.9 million attributable to accident year 2025 and unfavorable development of $0.8 million attributable to accident year 2024 and prior. The unfavorable development for accident year 2025 and prior was primarily driven by higher than expected frequency of claims.

Reserve for veterinary invoices, by year of occurrence

In the following tables, the reserve for veterinary invoices for each segment is presented as the amount (in thousands) by the year to which the veterinary invoice relates, referred to as the year of occurrence.

SubscriptionAs of March 31, 2026
Year of Occurrence
2024 and prior$2,962
20256,678
202618,798
$28,438
Other BusinessAs of March 31, 2026
Year of Occurrence
2024 and prior$1,729
20254,950
202621,584
$28,263
  1. Debt

Prior Credit Facility

On March 25, 2022, the Company entered into a credit agreement with Piper Sandler Finance, LLC, acting as the administrative agent, that provided the Company with $150.0 million in credit (the "Prior Credit Facility"). The Prior Credit Facility obligated the Company to repay 0.25% of any then-outstanding Term Loans, together with accrued and unpaid interest, on a quarterly basis. In November 2025, the Company repaid the Prior Credit Facility in full utilizing proceeds from the PNC Facility.

PNC Facility

On November 4, 2025, the Company entered into a credit agreement with PNC Bank, National Association acting as the administrative agent, that provides the Company with $120.0 million in credit (the "PNC Facility") consisting of:

(a) an initial term loan in an aggregate principal amount of $100.0 million ("PNC Initial Term Loan"), which was funded at closing;

(b) commitments for revolving loans in an aggregate principal amount at any time outstanding not in excess of $20.0 million (PNC Revolving Loans), of which $15.0 million was drawn and the rest may be drawn at any time prior to maturity.

The PNC Facility is secured by substantially all assets of the Company and its subsidiaries. Proceeds from the PNC Facility were utilized to pay off the Prior Credit Facility. The credit agreement with PNC Bank contains financial and other covenants. As of March 31, 2026, the Company was in compliance with all financial and other covenants.

To the extent not previously paid, the PNC Facility is due and payable on November 4, 2028. The Company will make quarterly principal payments of $2.5 million on the PNC Initial Term Loan. The Company may voluntarily prepay loans or reduce revolving commitments under the PNC Facility at any time without premium or penalty.

Loans under the PNC Facility bear interest at a reference rate plus an applicable margin, which will generally be the SOFR reference rate plus 2.75% per annum. The stated interest rate as of March 31, 2026 was approximately 6.45% for the aggregate outstanding term loans. The Company incurred total debt issuance cost of approximately $0.8 million, which is reported in the Consolidated Balance Sheet as a direct reduction from the carrying amount of the PNC Facility, and is amortized as interest expense over the term of three years.

Future principal payments on outstanding borrowings as of March 31, 2026 are as follows (in thousands):

Year Ending December 31,As of March 31, 2026
2026$7,500
202710,000
202892,500
Total$110,000
  1. Stock-Based Compensation

Stock-based compensation expense includes restricted stock units granted to employees and other service providers and has been reported in the Company’s Consolidated Statements of Operations depending on the function performed by the employee or other service provider. Stock-based compensation expense recognized in each category of the Consolidated Statements of Operations was as follows (in thousands):

Three Months Ended March 31,
20262025
Veterinary invoice expense$560$770
Other cost of revenue569489
Technology and development1,5071,151
General and administrative4,8934,528
New pet acquisition expense1,4712,892
Total expensed stock-based compensation9,0009,830
Capitalized stock-based compensation3249
Total stock-based compensation$9,032$9,879

Stock Options

The following table presents information regarding stock options granted, exercised, and forfeited for the period presented:

Number of OptionsWeighted Average Exercise Price per ShareAggregate Intrinsic Value (in thousands)
Outstanding as of December 31, 2025197,232$16.20$4,175
Granted———
Exercised(27,233)9.53690
Forfeited(1,476)9.36—
Outstanding as of March 31, 2026168,52317.341,394
Exercisable as of March 31, 2026168,523$17.34$1,394

As of March 31, 2026, stock options outstanding and stock options exercisable had a weighted average remaining contractual life of 1.0 year.

The Company has not granted any new stock options since 2017 and all outstanding options vested prior to January 1, 2022. The Company issues authorized shares upon the exercise of stock options.

Restricted Stock Units

The following table presents information regarding restricted stock units granted, vested and forfeited for the period presented:

Number of SharesWeighted AverageGrant Date Fair Value per Share
Unvested shares as of December 31, 20251,014,774$40.32
Granted761,41528.73
Vested(210,356)42.00
Forfeited(18,305)41.29
Unvested shares as of March 31, 20261,547,528$34.37

Stock-based compensation expenses of $49.9 million related to unvested restricted stock units are expected to be recognized over a weighted average period of approximately 2.0 years.

  1. Stockholders' Equity

Common Stock and Preferred Stock

As of March 31, 2026, the Company had 100,000,000 shares of common stock authorized and 43,620,614 shares of common stock outstanding. Holders of common stock are entitled to one vote on each matter properly submitted to the stockholders of the Company except those related to matters concerning possible outstanding preferred stock. At March 31, 2026, the Company had 10,000,000 shares of undesignated preferred stock authorized for future issuance and did not have any outstanding shares of preferred stock. The holders of common stock are also entitled to receive dividends as and when declared by the board of directors of the Company (the Board), whenever funds are legally available. These rights are subordinate to the dividend rights of holders of any senior classes of stock outstanding at the time. The Company does not intend to declare or pay any cash dividends in the foreseeable future.

Share Repurchase Program

In April 2021, the Board approved a share repurchase program, pursuant to which the Company may, between May 2021 and May 2026, repurchase outstanding shares of the Company's common stock. The Company repurchasedno shares during the three months ended March 31, 2026 and 2025, respectively.

  1. Accumulated Comprehensive Income (Loss)

A summary of the components of Accumulated other comprehensive income (loss) is as follows (in thousands):

Three months ended March 31, 2026Foreign Currency TranslationNet Unrealized Gain (Loss) on Available-for-Sale SecuritiesTotal
Balance as of January 1, 2026$720$1,377$2,097
Other comprehensive income(1,277)(1,513)(2,790)
Balance as of March 31, 2026$(557)$(136)$(693)
Three months ended March 31, 2025Foreign Currency TranslationNet Unrealized Gain on Available-for-Sale SecuritiesTotal
Balance as of January 1, 2025$(3,113)$501$(2,612)
Other comprehensive income1,3525451,897
Balance as of March 31, 2025$(1,761)$1,046$(715)
  1. Segments

The Company hastwo reporting segments: subscription business and other business. The subscription business segment generates revenue primarily from subscription payments related to the Company's direct-to-consumer products. The other business segment generates revenue from other product offerings, primarily by underwriting policies on behalf of third parties with whom the Company has a business-to-business relationship. The other business segment has, and targets, a lower margin profile than the Company's subscription business segment. The Company does not undertake marketing efforts for these policies and has a business-to-business relationship with these third-parties.

The Company's chief operating decision maker is its Chief Executive Officer. The chief operating decision maker reviews revenue and operating income (loss) to evaluate segment performance. Revenue, veterinary invoice expense, other cost of revenue, and new pet acquisition expenses are generally directly attributed to each segment. Other operating expenses, such as technology and development expense, general and administrative expense, and depreciation and amortization, are generally allocated proportionately based on revenue in each segment. Interest and other expenses and income taxes are not allocated to the segments, nor included in the measure of segment profit or loss. The Company does not analyze discrete segment balance sheet information related to long-term assets. Substantially all of the Company’s long-lived assets were located in the United States as of March 31, 2026 and December 31, 2025.

Operating income (loss)of the Company’s segments was as follows (in thousands):

Three Months Ended March 31,
20262025
Subscription business:
Revenue$269,454$233,064
Veterinary invoice expense191,414168,181
Other cost of revenue25,03821,664
Technology and development7,9245,501
General and administrative13,40213,557
New pet acquisition expense22,58320,512
Depreciation and amortization2,6002,584
Subscription business operating income6,4931,065
Other business:
Revenue114,595108,911
Veterinary invoice expense90,02279,269
Other cost of revenue16,08621,758
Technology and development3,3702,571
General and administrative5,7006,335
New pet acquisition expense284
Depreciation and amortization1,1061,207
Other business operating loss(1,717)(2,233)
Loss from investment in joint venture—(305)
Operating income (loss)4,776(1,473)
Interest expense1,8753,211
Other (income), net(3,055)(3,240)
Income (loss) before income taxes$5,956$(1,444)

The following table presents the Company’s revenue by geographic region of the member (in thousands):

Three Months Ended March 31,
20262025
United States$318,178$285,824
Canada and other65,87156,150
Total revenue$384,049$341,975
  1. Income Taxes

The effective tax rate for the quarter ended March 31, 2026 was 18.1% compared to (2.7)% for the quarter ended March 31, 2025, primarily due to the transfer of our Canadian insurance business to GPIC, resulting in an increase in taxable income in Canada.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.